Sha Meng, Cao Jie, Qin Cheng Lin, Zhang Jian, Fan Chao, Li Zhe, Tong Ying, Xia Lei, Zhang Jian Jun, Xia Qiang
Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
These authors contributed equally to this work.
World J Oncol. 2024 Aug;15(4):579-591. doi: 10.14740/wjon1895. Epub 2024 Jul 5.
Lymph node status is a prominent prognostic factor for intrahepatic cholangiocarcinoma (ICC). However, the prognostic value of performing lymph node dissection (LND) in patients with clinical node-negative ICC remains controversial. The aim of this study was to evaluate the clinical value of LND on long-term outcomes in this subgroup of patients.
We retrospectively analyzed patients who underwent radical liver resection for clinically node-negative ICC from three tertiary hepatobiliary centers. The propensity score matching analysis at 1:1 ratio based on clinicopathological data was conducted between patients with and without LND. Recurrence-free survival (RFS) and overall survival (OS) were compared in the matched cohort.
Among 303 patients who underwent radical liver resection for ICC, 48 patients with clinically positive nodes were excluded, and a total of 159 clinically node-negative ICC patients were finally eligible for the study, with 102 in the LND group and 57 in the non-LND group. After propensity score matching, two well-balanced groups of 51 patients each were analyzed. No significant difference of median RFS (12.0 vs. 10.0 months, P = 0.37) and median OS (22.0 vs. 26.0 months, P = 0.47) was observed between the LND and non-LND group. Also, LND was not identified as one of the independent risks for survival. Among 51 patients who received LND, 11 patients were with positive lymph nodes (lymph node metastasis (LNM) (+)) and presented significantly worse outcomes than those with LND (-). On the other hand, postoperative adjuvant therapy was the independent risk factor for both RFS (hazard ratio (HR): 0.623, 95% confidence interval (CI): 0.393 - 0.987, P = 0.044) and OS (HR: 0.585, 95% CI: 0.359 - 0.952, P = 0.031). Furthermore, postoperative adjuvant therapy was associated with prolonged survivals of non-LND patients (P = 0.02 for RFS and P = 0.03 for OS).
Based on the data, we found that LND did not significantly improve the prognosis of patients with clinically node-negative ICC. Postoperative adjuvant therapy was associated with prolonged survival of ICC patients, especially in non-LND individuals.
淋巴结状态是肝内胆管癌(ICC)的一个重要预后因素。然而,对临床淋巴结阴性的ICC患者进行淋巴结清扫(LND)的预后价值仍存在争议。本研究的目的是评估LND对该亚组患者长期预后的临床价值。
我们回顾性分析了来自三个三级肝胆中心接受根治性肝切除术治疗临床淋巴结阴性ICC的患者。根据临床病理数据,对接受LND和未接受LND的患者进行1:1比例的倾向评分匹配分析。在匹配队列中比较无复发生存期(RFS)和总生存期(OS)。
在303例接受ICC根治性肝切除术的患者中,排除48例临床淋巴结阳性患者,最终共有159例临床淋巴结阴性的ICC患者符合研究条件,其中LND组102例,非LND组57例。经过倾向评分匹配后,对两组各51例平衡良好的患者进行分析。LND组和非LND组之间的中位RFS(12.0个月对10.0个月,P = 0.37)和中位OS(22.0个月对26.0个月,P = 0.47)无显著差异。此外,LND未被确定为生存的独立风险因素之一。在51例接受LND的患者中,11例淋巴结阳性(淋巴结转移(LNM)(+)),其预后明显差于LND(-)的患者。另一方面,术后辅助治疗是RFS(风险比(HR):0.623,95%置信区间(CI):0.393 - 0.987,P = 0.044)和OS(HR:0.585,95%CI:0.359 - 0.952,P = 0.031)的独立风险因素。此外,术后辅助治疗与非LND患者的生存期延长相关(RFS为P = 0.02,OS为P = 0.03)。
基于这些数据,我们发现LND并未显著改善临床淋巴结阴性ICC患者的预后。术后辅助治疗与ICC患者的生存期延长相关,尤其是在非LND患者中。